Literature DB >> 22206855

Receptor changes in metachronous breast tumors--our experience of 10 years.

Jasneet Singh Bhullar1, Amruta Unawane, Gokulakkrishna Subhas, Husein Poonawala, Linda Dubay, Lorenzo Ferguson, Yousif Goriel, Michael J Jacobs, Ramachandra B Kolachalam, Sumet Silapaswan, Vijay K Mittal.   

Abstract

INTRODUCTION: Patients with primary breast cancer (PBC) are at 2 to 6 times higher risk for developing synchronous and metachronous breast cancer (MBC). The pathology and behavior of MBC still remains unclear.
METHODS: We reviewed the charts of 108 women with MBC at our hospital over the past 10 years. Profile patterns of the estrogen receptor (ER), the progesterone receptor (PR), and Her2/neu receptors were explored.
RESULTS: Of 33 patients with ER(+)/PR(+) in the primary tumor, 23 (70%) retained the status in MBC. Forty-five (92%) of 49 patients with ER(-)/PR(-) in the primary tumor remained the same in MBC. Most Her2(-) tumors (22/31, 71%) remained negative, but 50% (8/16) of Her2(+) tumors became negative.
CONCLUSIONS: Most MBC retained the ER/PR expression patterns irrespective of the treatment for the primary tumor, thus suggesting a common origin. Because MBCs tend to be triple negative and thus more aggressive, early detection and close surveillance techniques must be devised.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22206855     DOI: 10.1016/j.amjsurg.2011.09.010

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  The prognosis of synchronous and metachronous bilateral breast cancer in Chinese patients.

Authors:  Xinrui Liang; Danhua Li; Wenwen Geng; Xuchen Cao; Chunhua Xiao
Journal:  Tumour Biol       Date:  2013-01-09

2.  Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

Authors:  Elżbieta Senkus; Jolanta Szade; Beata Pieczyńska; Anna Zaczek; Joanna Pikiel; Katarzyna Sosińska-Mielcarek; Agnieszka Karpińska; Jacek Jassem
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.